

Menarini

[View the current Menarini Page on BioPortfolio.com](http://www.bioportfolio.com)

(<http://www.bioportfolio.com/biocorporate/6932-Menarini.html>)

Contact Details:

Via Sette Santi 3
Florence

Tel: +390555680658
Fax: 3.9055568045e+011
Email: dsher@tin.it

50131
Italy



Recent Publications by Menarini:

- [Pharmacological characterization of the bradykinin B2 receptor antagonist MEN16132 in rat in vitro bioassays.](#)
The pharmacological profile of the bradykinin B(2) receptor antagonist... 11th November, 2009
Menarini Ricerche S.p.A., Department of Pharmacology, via Rismondo 12A,- Eur J Pharmacol. 2009 Aug 1;615(1-3):10-6. Epub 2009 May 13. ([DOI Direct Link](#))
- [Antitumor activity of delimotecan against human metastatic melanoma: pharmacokinetics and molecular determinants.](#)
Delimotecan (MEN 4901/T-0128) is a new cytotoxic prodrug constituted by a... 6th November, 2009
Pharmacology Department of Menarini Ricerche SpA, Pomezia, Rome, Italy.- Int J Cancer. 2009 Nov 15;125(10):2456-64. ([DOI Direct Link](#))
- [Role of calcitonin gene-related Peptide in gastric mucosal defence and healing.](#)
Calcitonin gene-related peptide (CGRP) is a polypeptide produced by... 29th October, 2009
Menarini Ricerche SpA, Department of Preclinical Development, Firenze,- Curr Pharm Des. 2009;15(30):3571-6.
- [Cyclic glycopeptidomimetics through a versatile sugar-based scaffold.](#)
Cyclic peptidomimetics are attracting structures to obtain a distinct,... 29th October, 2009
Menarini Ricerche SpA, Firenze, Italy.- Bioorg Med Chem Lett. 2009 Jul 15;19(14):3841-4. Epub 2009 Apr 9. ([DOI Direct Link](#))
- [Structural characterization of the regioisomers of di\(hydroxybutyl\) ether by GC-EI MS and theoretical calculations.](#)
Di(hydroxybutyl) ether (DHBE), a liver protecting drug, is composed of a... 1st October, 2009

- Menarini Manufacturing, Logistics and Services Srl, via Sette Santi 3,- J Mass Spectrom. 2009 Jul;44(7):1081-6. ([DOI Direct Link](#))
- [Chemically distinct HDAC inhibitors prevent adipose conversion of subcutaneous human white preadipocytes at an early stage of the differentiation program.](#)
*The present study investigated the effect of HDAC inhibitors on the...*22nd September, 2009
 Pharmacology Department, Menarini Ricerche SpA, Florence, Italy.- Exp Cell Res. 2009 Nov 15;315(19):3267-80. Epub 2009 Sep 18. ([DOI Direct Link](#))
 - [Effect of intra-articular MEN16132, a kinin B2 receptor antagonist, on nociceptive response in monosodium iodoacetate-induced experimental osteoarthritis in rats.](#)
*The present study was designed to investigate the role of BK in the knee...*12th September, 2009
 Pharmacology Department, Menarini Ricerche S.p.A.- J Pharmacol Exp Ther. 2009 Sep 10. ([DOI Direct Link](#))
 - [Bradykinin receptor antagonists--a review of the patent literature 2005-2008.](#)
*BACKGROUND: For > 20 years, pharmaceutical companies and academic centers...*3rd September, 2009
 Menarini Ricerche S.p.A., Via Tito Speri 10, Pomezia, Rome, Italy.- Expert Opin Ther Pat. 2009 Jul;19(7):919-41. ([DOI Direct Link](#))
 - [Excitatory and inhibitory urinary bladder reflexes induced by stimulation of cervicovaginal capsaicin-sensitive sensory fibers in rats.](#)
*We have investigated the effect of intravaginal application of capsaicin...*15th July, 2009
 Department of Pharmacology, Menarini Ricerche S.p.A., via Rismondo 12A,- Naunyn Schmiedebergs Arch Pharmacol. 2009 Feb;379(2):107-14. Epub 2008 Oct ([DOI Direct Link](#))
 - [Forces determining the adsorption of a monoclonal antibody onto an aluminium hydroxide adjuvant: influence of interstitial fluid components.](#)
*This study evaluates the forces involved in the adsorption of abagovomab...*16th May, 2009
 Berlin-Chemie AG/Menarini, Glienicke Weg 125, 12489 Berlin, Germany.- Vaccine. 2009 Mar 13;27(12):1834-40. Epub 2009 Feb 4. ([DOI Direct Link](#))
 - [Tricyclic structures in medicinal chemistry: an overview of their recent uses in non-CNS pathologies.](#)
*Tricyclic compounds are sometimes considered as synonyms of drugs healing...*6th March, 2009
 Chemistry Department, Menarini Ricerche S.p.A., Via dei Sette Santi, 3,- Mini Rev Med Chem. 2008 Dec;8(14):1464-84.
 - [Spatial and temporal expression of tachykinins and NK1- and NK2-receptor gene during TNB induced colitis in rats.](#)
*The distribution and modification of the tachykinins Substance P (SP) and...*20th February, 2009
 Department of Pharmacology, Menarini Ricerche S.p.A., Via Sette Santi 1,- Neuropeptides. 2008 Oct-Dec;42(5-6):663-70. Epub 2008 Aug 19. ([DOI Direct Link](#))
 - [Knee osteoarthritis: a role for bradykinin?](#)
*Osteoarthritis (OA) is a painful and degenerating progressive disease of...*17th December, 2008
 Pharmacology Department, Menarini Ricerche S.p.A., via Rismondo 12A,- Inflamm Res. 2008 Aug;57(8):351-61. ([DOI Direct Link](#))
 - [Tachykinin receptors and gastrointestinal motility: focus on humans.](#)
*Peptides of the tachykinin (TK) family were first discovered in the...*15th November, 2008
 Clinical Research Department, Menarini Ricerche, Florence, Italy.- Eur Rev Med Pharmacol Sci. 2008 Aug;12 Suppl 1:69-80.

Press Releases on Menarini:

Reportlinker Adds Point of Care Diagnostics 2010 and Beyond: Rapid Testing at a Crossroads	5th November, 2009	Reportlinker	<p>NEW YORK, Nov. 5 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Point of Care Diagnostics 2010 and Beyond: Rapid Testing at a Crossroads</p>
Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment	26th October, 2009	Reportlinker	<p>-- A focus on "engineered" antibodies Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment reviews the broad drug development effort that is focused on bringing</p>
Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech	6th October, 2009	Reportlinker	<p>NEW YORK, Oct. 6 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and</p>
Leading Italian Pharmaceutical Group Deploys TrackWise(R) Solution to Improve Quality Processes	11th May, 2009	Sparta Systems, Inc.	<p>Menarini Group chooses Enterprise Quality Management Solution to manage quality and maintain regulatory compliance HOLMDEL, N.J., May 11 /PRNewswire/ -- Sparta Systems, Inc., the maker of TrackWise(R)</p>
CV Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results	20th February, 2009	CV Therapeutics, Inc.	<p>- 64 percent year-over-year increase in Ranexa(R) net revenue - - Company retires more than \$100 million in convertible debt in 2008 - - Ranexa prescriptions for first week in February hit record</p>

- [Ipsen Grants Menarini Exclusive European Licence Rights to Adenuric \(Febuxostat\), Its Novel Treatment for Chro](#)
Pharma Live: Oct 22 2009 5:04AM Matching: menarini
- [Ipsen Licenses New Gout Drug to Menarini in ?132M Deal](#)
Therapeutics Daily: Oct 21 2009 1:18AM Matching: menarini
- [Menarini granted exclusive European licence rights to Ipsen's Adenuric](#)
News-Medical.Net: Oct 20 2009 6:28AM Matching: menarini
- [Ipsen Grants Menarini Exclusive European Licence Rights to Adenuric \(Febuxostat\), Its Novel Treatment for Chronic Hyperuricaemia in Gout](#)
Yahoo! Canada: Oct 20 2009 8:10PM Matching: menarini
- [Ipsen Grants Menarini Exclusive European Licence Rights to Adenuric \(Febuxostat\), Its Novel Treatment for Ch](#)
Genetic Engineering News: Oct 20 2009 6:41AM Matching: menarini
- [Ipsen Grants Menarini Exclusive European Licence Rights to Adenuric \(Febuxostat\), Its Novel Treatment for Chronic Hyperuricaemia in Gout](#)
SmartBrief: Oct 20 2009 6:22AM Matching: menarini
- [Exclusive European Sublicensing Agreement Signed for Teijin-developed TMX-67 Gout Treatment](#)
Pharma Live: Oct 20 2009 5:37PM Matching: menarini
- [Menarini to Market Takeda/Ipsen Gout Therapy in 41 European Countries](#)
Genetic Engineering News: Oct 20 2009 6:19PM Matching: menarini
- [Ipsen signs co-promotion agreement with Menarini for Adenuric\(R\) \(Febuxostat\)](#)
Individual.com: Oct 20 2009 7:13PM Matching: menarini
- [Teijin Pharma Limited: Exclusive European Sublicensing Agreement Signed for Teijin-developed TMX-67 Gout Treatment](#)
Individual.com: Oct 20 2009 9:50AM Matching: menarini

Menarini Clinical Trials:



- [Effects of Nebivolol on Subclinical Left Ventricular dySfunction: A Comparative Study Against Metoprolol](#)

Menarini Patents:



- 3968145- [Methyl 2\(1 chloronaphth-2-yloxy\)propionate](#)
- 5045234- [Solution for controlling the performance of the ionic exchange chromatography column of HPLC \(High Performance Liquid Chromatography\) apparatuses, and a process for preparing the same](#)
- 5077199- [Ready to use liquid reagent for determining the glucose content in blood](#)

- 5080905- [Therapy of 10-amino-5,6-dihydro-11H-dibenzo\(b,e\)azepine-6,11-dione and derivatives as drugs for use in the treatment of urinary incontinence](#)
- 5128447- [Synthetic peptide antagonists of neurokinin A, salts thereof and respective preparation processes](#)
- 5324479- [Analyzer for the determination of the phenotype and the ABO blood group](#)
- 5472976- [Poly 4-aminopyrrole-2-carboxamide derivatives, and pharmaceutical compositions which contain them](#)
- 5516690- [Ketoprofen resolution by ester hydrolysis using Trichosporon laibacchii](#)
- 5554789- [Arylpropionic derivative, a process for the preparation and the use thereof as an analgesic agent](#)
- 5641802- [Tachyquinine antagonists, their preparation and use in pharmaceutical formulations](#)
- 5011833- [Novel derivatives of 6,11-dihydro-dibenzo\(C,F\)\(1,2,5\)-thiadiazepine 5,5-dioxide, salts thereof and appropriate processes for the preparation thereof](#)
- 4978772- [Utilization of otilonium bromide \(DCI\) for topical application in the gastrointestinal tract and related pharmaceutical formulation appropriate for such use](#)
- 4185124- [2-\(4-Biphenyl\)-N-\(2-diethylamino alkyl\)propionamide and salts thereof used as spasmolytic agents](#)
- 4188323- [Derivatives of 2-oxazolydone and methods for preparing the same](#)
- 4296124- [Pharmaceutical methods](#)
- 4372958- [Compound having antitussive activity](#)
- 4485112- [N-\[\(Benzofuran-2-yl\)\(phenyl\)methyl\]-alkylene diamines useful in treating arrhythmic, histaminic and tussive conditions](#)
- 4503075- [Derivatives of 1-alkylamine-3\[4\(p-alkyloxy-benzamide\)phenoxy\]-2-propanol, having beta-sympatholytic activity, their salts, and production processes thereof](#)
- 4551451- [Tricyclic derivatives of 5,6-dihydro-11H-dibenzo \(b,e\) azepin-6-one having pharmacological activity](#)
- 4604392- [2-substituted benzofuran derivatives useful in treating cardiac arrhythmic, histaminic and tussive conditions](#)
- 4800208- [\(Benzofuran-2-yl\)imidazoles having pharmaceutical activity, their salts and relevant production processes](#)
- 5670534- [Distamycin a derivatives as anti-malarial agents](#)
- 5698710- [Tachykinins antagonists](#)
- 5700677- [Protein analogues of tissue plasminogen activator](#)
- 6521760- [Process for the preparation of zofenopril calcium salt](#)
- 6618603- [Apparatus for measurement and control of the content of glucose, lactate or other metabolites in biological fluids](#)
- 6653289- [L-arabino-disaccharides of anthracyclines, processes for their preparation, and pharmaceutical compositions containing them](#)
- 6780968- [Monocyclic compounds with four bifunctional residues having NK-2 antagonist action](#)
- 6864366- [Process for the preparation of \(e\)-5-\(2-bromovinyl\)-2'-deoxyuridine](#)
- 6921841- [Process for the synthesis of optically active anthracyclines](#)
- 7015196- [Basic monocyclic compounds having Nk2 antagonist action, processes for their preparation, and formulations containing them](#)
- 7067154- [Pharmaceutical compositions containing Vitamin D and calcium, their preparation and therapeutic use](#)
- 7273856- [Linear basic compounds having NK-2 antagonist activity and formulations thereof](#)
- 6515012- [Process for the preparation of zofenopril calcium salt](#)
- 6153747- [Process for the preparation of 2-halomethyl-penems and their use for the preparation of antibacterial penems](#)
- 5747483- [Penem derivatives, their preparation and pharmaceutical compositions containing them](#)
- 5801152- [Antracycline disaccharides, process for their preparation, and pharmaceutical compositions containing them](#)
- 5807835- [3'-Deamino-4'-deoxy-4'-amino-8-fluoroanthracyclines](#)

- 5814608- [S-fluoro-anthracyclines, processes for their preparation and pharmaceutical compositions containing them](#)
- 5849795- [Tachykinins antagonists](#)
- 5912164- [Stereoselective hydrolysis of chiral carboxylic acid esters using esterase from ophiostoma or ceratocystis](#)
- 5916773- [Recombinant production of fusion proteins comprising erythropoietin and GM-CSF components](#)
- 5990142- [Benzopyran derivatives having leukotriene-antagonistic action](#)
- 6150325- [Bicyclic tachykinins antagonists, preparation thereof and their use in pharmaceutical compositions](#)
- 7491825- [Basic non-peptide bradykinin antagonists and pharmaceutical compositions therefrom](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road,

